Abstract
: PSA is the most routine marker to detect prostate cancer, but due to its low specificity that can lead to a number of unnecessary biopsies, there is great need for an alternate method. Can PCA3 be one of these methods? PCA3 is overexpressed in prostate cancer, not in benign conditions such as prostatitis (unlike PSA). Because of its efficacy (being more sensitive and specific in comparison with PSA), this biomarker could be a very useful and promising method for the early detection of prostate cancer, especially in combination with other tests such as TMPRSS2-ERG gene fusion.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
